Doxorubicin Market: Information by Application (liver cancer, lung cancer), By Distribution Channel (hospital pharmacy, retail pharmacy) – Global Forecast Till 2023
Doxorubicin Market Analysis
Global doxorubicin market size is projected to have a steady growth rate at a whopping 6.5% CAGR over the forecast period (2016-2023). Doxorubicin or anthracycline is a form of chemotherapy medicine that is used for diminishing or reducing growth of cancer cells via blocking the topo isomerase enzyme. This drug is utilized alone or together with other drugs for treating various types of cancers such as ovarian, stomach, bladder, lung, breast, non-Hodgkin and Hodgkin lymphomas, neuroblastoma and specific forms of leukemia. The treatment rests upon the cancer type being treated, how well a patient responds to the medicine and other forms of drugs that the patient takes at the time of the treatment. Doxorubicin comes in both lyophilized power form and injection solution. It is generally administered intravenously through central venous catheters (CVC) or peripheral inserted central line catheters (PICC).
There are abundant factors that is propelling the growth of the doxorubicin market. These factors as per the MRFR (Market Research Future) report include increasing prevalence of various forms of cancer, boost in geriatric population, growing awareness of cancer treatment and inclusion of the drug in different applications such as AIDS-related Kaposi Sarcoma and neuroblastoma, growing cancer treatment awareness programs, large presence of ablation and surgical centers and technological advancements. On the contrary stringent regulatory authorities, various cost suppression measures undertaken by different governments and numerous side effects resulting from doxorubicin are factors that are likely to hamper the growth of the doxorubicin market. Some of the common side effects of taking doxorubicin include inflammation of the mouth, rash, vomiting, bone marrow suppression, hair loss, allergic reactions namely anaphylaxis, damage of tissue owing to the position of the injection, heart damage, treatment associated to leukemia and radiation recall. All these side effects and more are affecting the doxorubicin market growth.
Get a FREE Sample Copy of Report with Complete TOC @ https://www.marketresearchfuture.com/sample_request/7376
Doxorubicin Market Key Players
Leading players profiled in the doxorubicin market include
- GLENMARK PHARMACEUTICALS LTD
- Teva Pharmaceuticals
- Dr. Reddy’s Laboratories Ltd.
- Sandoz
- Novartis AG
- Accord Healthcare
- Janssen Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
Doxorubicin Market Segmentation
MRFR report offers a broad segmental analysis of the doxorubicin market on the basis of application and distribution channel.
Global Doxorubicin Market, by Application
- Liver cancer
- Gastric cancer
- Breast cancer
- Bone sarcoma
- Prostate cancer
- Stomach Cancer
- Ovarian cancer
- Leukemia
- others
Global Doxorubicin Market, by Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Others
Regional Analysis
By region, the doxorubicin market covers growth opportunities and latest trends across Americas, the Middle East and Africa, Europe and Asia Pacific. Of these, the Americas will remain the vital contributor in the market over the forecast period. Factors attributed for the market growth in this region include favorable regulatory authorities and reimbursement, awareness about cancer treatment, increase in cancer cases and presence of leading manufacturers. The doxorubicin market in Europe will account for the second major share owing to rising healthcare expenditure and increasing pool of cancer patients. In the APAC region, the doxorubicin market is projected to grow at the fastest pace over the forecast period. This is on account of growing geriatric population especially in China and India, growing number of manufacturers looking for opportunities in developing countries, government investment and initiatives for the healthcare sector development and increasing cancer treatment awareness programs. On the other hand, the doxorubicin market in the Middle East and Africa is prognosticated to have minimal share over the forecast period.
Doxorubicin Industry Update/News
March 2019 – SourcingLink.net, Inc. (SNET) has lately revealed the news of entering into a worldwide exclusive licensing agreement with leading biopharmaceutical company, NanoSmart Pharmaceuticals, Inc. This agreement has been made for the right of utilizing nanoparticle platform technologies of NanoSmart for developing and commercializing doxorubicin’s improved formulations to treat human cancers. It will impact countless cancer patients all across the world and also offer the increasing global cancer population with enhanced therapy options, including patients with unmet rare cancer needs.
Get More Information on Doxorubicin Market Research Report – Global Forecast till 2023 @ https://www.marketresearchfuture.com/reports/doxorubicin-market-7376
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312